Seeking Alpha

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm...

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm believes the pullback following the company's disappointing Q1 results is due to transient issues, and the company is still on track for Q2. The firm maintains its buy rating on the shares.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs